Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
- PMID: 19155272
- DOI: 10.1093/brain/awn349
Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
Abstract
A number of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy are characterized by the formation and intraneuronal accumulation of fibrillar aggregates of alpha-synuclein (alpha-syn) protein in affected brain regions. These and other findings suggest that the accumulation of alpha-syn in the brain plays an important role in the pathogenesis of these diseases. However, more recently it has been reported that early amyloid aggregates or 'soluble oligomers' are the pathogenic species that lead to neurodegeneration and neuronal cell death rather than the later 'mature fibrils'. In this study, we investigated the presence of alpha-syn oligomers in brain lysates prepared from frozen post-mortem brains of normal, Alzheimer's disease and DLB patients. The brain extracts were subjected to high speed centrifugation, to remove insoluble alpha-syn aggregates, followed by specific detection of soluble oligomers in the supernatants by employing FILA-1, an antibody that specifically binds to alpha-syn aggregates, but not to alpha-syn monomers, or to tau or beta-amyloid aggregates. Using this novel enzyme-linked immunosorbent assay (ELISA) method to quantify the amounts of alpha-syn oligomers in the brain extracts, our data clearly show an increase in the levels of soluble oligomers of alpha-syn in the DLB brains compared to those with Alzheimer's disease and the controls (P < 0.0001). Our findings provide strong evidence to support the contention that elevated soluble oligomers of alpha-syn are involved in the pathogenesis of DLB. Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of alpha-syn in human brain lysates.
Similar articles
-
Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.Neuropathol Appl Neurobiol. 2019 Oct;45(6):597-608. doi: 10.1111/nan.12531. Epub 2018 Dec 3. Neuropathol Appl Neurobiol. 2019. PMID: 30422353
-
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30. Neurobiol Dis. 2015. PMID: 25937088
-
Stabilization of α-synuclein oligomers using formaldehyde.PLoS One. 2019 Oct 11;14(10):e0216764. doi: 10.1371/journal.pone.0216764. eCollection 2019. PLoS One. 2019. PMID: 31603909 Free PMC article.
-
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.Prog Neurobiol. 2022 Jul;214:102270. doi: 10.1016/j.pneurobio.2022.102270. Epub 2022 Apr 18. Prog Neurobiol. 2022. PMID: 35447272 Review.
-
Small molecule-based fluorescent probes for the detection of α-Synuclein aggregation states.Bioorg Med Chem Lett. 2023 Apr 15;86:129257. doi: 10.1016/j.bmcl.2023.129257. Epub 2023 Mar 24. Bioorg Med Chem Lett. 2023. PMID: 36966976 Review.
Cited by
-
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.Brain. 2013 Feb;136(Pt 2):412-32. doi: 10.1093/brain/aws358. Brain. 2013. PMID: 23413261 Free PMC article.
-
Monitoring α-synuclein aggregation.Neurobiol Dis. 2023 Jan;176:105966. doi: 10.1016/j.nbd.2022.105966. Epub 2022 Dec 15. Neurobiol Dis. 2023. PMID: 36527982 Free PMC article. Review.
-
Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.Cell Mol Life Sci. 2022 Mar 4;79(3):174. doi: 10.1007/s00018-022-04166-9. Cell Mol Life Sci. 2022. PMID: 35244787 Free PMC article. Review.
-
CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation.Cells. 2021 Oct 21;10(11):2830. doi: 10.3390/cells10112830. Cells. 2021. PMID: 34831053 Free PMC article.
-
Exercise Dosage in Reducing the Risk of Dementia Development: Mode, Duration, and Intensity-A Narrative Review.Int J Environ Res Public Health. 2021 Dec 17;18(24):13331. doi: 10.3390/ijerph182413331. Int J Environ Res Public Health. 2021. PMID: 34948942 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous